Cost and access to weight-loss drugs While highly effective, GLP-1 medications come at a steep priceup to $1,349 per month, often only partially covered by insurance
One of the reasons retatrutide is generating significant excitement in the field of metabolic health is its comprehensive range of potential secondary benefits
Higher risks may occur when patients: self-dose without supervision buy peptides from unregulated websites use incorrect dosing combine multiple peptides improperly skip follow-up monitoring ignore nutrition and hydration Patients sometimes assume peptide therapy is natural and therefore completely risk-free
Its another new, expensive drug, which flags women with better access to care

[31] A large study found that GLP-1 RA use was associated with lower risk of developing immune-mediated inflammatory diseases in patients with type 2 diabetes or obesity, suggesting a potential protective effect in some cohorts.[42] What the science is showing is potential for improvements: GLP-1RAs reduce blunt activation in fibroblast-like synoviocytes and improve joint inflammation and metabolic parameters in rheumatoid arthritis models and small human cohorts.[26][29][25] [31] Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity.[31] Psoriasis showed improved PASI scores and quality-of-life metrics in patients with T2DM and psoriasis, alongside reductions in lesional skin and peripheral TNF-producing monocytes.[26] Case series show meaningful skin improvement.[26] In psoriasis and psoriatic arthritis , GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices
